Immunotherapy has been investigated in both preclinical studies and clinical trials as a new therapy for prostate cancer.
Vaccines, including those that utilize dendritic cells, viruses, or DNA, immunize against prostate-specific antigen and prostatic acid phosphatase. The vaccines have long been studied as monotherapy for the cancer, but increasingly more trials have been initiated in combination with other modalities. These include radiation, chemotherapy, and androgen deprivation therapy. This review describes and discusses the various combinations of vaccine immunotherapies.
Written by:
Uhlman MA, Bing MT, Lubaroff DM. Are you the author?
Department of Urology, University of Iowa, 375 Newton Road, Iowa City, IA, 52242, USA.
Reference: Immunol Res. 2014 May 18. Epub ahead of print.
doi: 10.1007/s12026-014-8532-1
PubMed Abstract
PMID: 24838261
UroToday.com Prostate Cancer Immunotherapy Section
